Breast CancerFDA Approvals, News & Updates

Kadcyla Approved for Adjuvant Treatment of HER2-Positive Early Breast Cancer with Residual Invasive Disease

June 2019 Vol 5 No 3

In May 2019, the FDA approved a new indication for Kadcyla (ado-trastuzumab emtansine; from Genentech) for adjuvant (additional) treatment of patients with HER2-positive early breast cancer and residual invasive disease after endocrine treatment with a taxane and Herceptin (trastuzumab). At the same time, the FDA approved 2 tests that should be used to select appropriate patients for adjuvant treatment with Kadcyla. Kadcyla was initially approved in 2013 for HER2-positive metastatic breast cancer.

This new approval was based on a clinical trial of 1486 patients with HER2-positive early breast cancer who received Kadcyla or Herceptin for a total of 14 cycles. After an average of 40 months, patients who received Kadcyla showed significant reduction in residual invasive disease versus those who received Herceptin. The most common side effects with Kad­cyla are fatigue, nausea, musculoskeletal and joint pain, bleeding, low platelet count, headache, and peripheral neuropathy.

Recommended For You
FDA Approvals, News & UpdatesLeukemia
Tibsovo Approved for First-Line Treatment of Patients with Acute Myeloid Leukemia and IDH1 Mutation
In May 2019, the FDA approved Tibsovo for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) and an IDH1 mutation, or for patients with AML who are unable to use intensive chemotherapy.
Breast CancerFDA Approvals, News & Updates
Piqray New Treatment Approved for Metastatic Breast Cancer and PI3KCA Mutation
In May 2019, the FDA approved Piqray (alpelisib), the first PI3K inhibitor for the treatment of metastatic breast cancer with a PI3KCA mutation in postmenopausal women, and in men. An FDA spokesperson said it was the first treatment “to demonstrate a clinically meaningful benefit” for this type of breast cancer.
Bladder CancerFDA Approvals, News & Updates
Balversa First Targeted Drug Approved for Metastatic Bladder Cancer with FGFR Genetic Alterations
In April 2019, the FDA approved Balversa, an FGFR kinase inhibitor, for the treatment of adults with advanced or metastatic bladder cancer and an FGFR genetic alteration, as determined by an FDA-approved diagnostic test. This is the first FDA-approved targeted drug for patients with this specific genetic mutation.
Breast CancerLymphomaSurvivorship
FDA Calls Attention to Risk Associated with Breast Implants: Anaplastic Large-Cell Lymphoma
By Kristen Chanley
In February 2019, the FDA issued a letter to raise awareness of the risk for a rare type of lymphoma, BIA-ALCL, that is linked to all types of breast implants. Although this is an uncommon reaction to implants, all women who have or intend to get an implant after breast cancer should be aware of this risk. Learn more about this risk here.
Last modified: July 15, 2019

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.